Veeva Systems Inc. (NYSE:VEEV) Shares Purchased by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. raised its holdings in shares of Veeva Systems Inc. (NYSE:VEEV) by 12.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,806 shares of the technology company’s stock after buying an additional 1,070 shares during the period. Daiwa Securities Group Inc.’s holdings in Veeva Systems were worth $1,888,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. UMB Bank n.a. lifted its position in Veeva Systems by 2.5% during the third quarter. UMB Bank n.a. now owns 2,103 shares of the technology company’s stock valued at $428,000 after buying an additional 51 shares in the last quarter. NewEdge Wealth LLC lifted its position in Veeva Systems by 0.6% during the third quarter. NewEdge Wealth LLC now owns 10,059 shares of the technology company’s stock valued at $2,047,000 after buying an additional 60 shares in the last quarter. Personal CFO Solutions LLC lifted its position in Veeva Systems by 5.9% during the third quarter. Personal CFO Solutions LLC now owns 1,091 shares of the technology company’s stock valued at $222,000 after buying an additional 61 shares in the last quarter. Sequoia Financial Advisors LLC lifted its position in Veeva Systems by 3.4% during the third quarter. Sequoia Financial Advisors LLC now owns 1,940 shares of the technology company’s stock valued at $395,000 after buying an additional 63 shares in the last quarter. Finally, Cape Investment Advisory Inc. lifted its position in shares of Veeva Systems by 3.0% during the third quarter. Cape Investment Advisory Inc. now owns 2,180 shares of the technology company’s stock worth $444,000 after purchasing an additional 64 shares in the last quarter. 88.20% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Veeva Systems

In other news, SVP Jonathan Faddis sold 3,598 shares of the company’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $207.42, for a total transaction of $746,297.16. Following the completion of the transaction, the senior vice president now owns 10,668 shares in the company, valued at $2,212,756.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, Director Timothy S. Cabral sold 15,000 shares of the company’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $226.04, for a total value of $3,390,600.00. Following the completion of the sale, the director now owns 23,391 shares of the company’s stock, valued at $5,287,301.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Jonathan Faddis sold 3,598 shares of the company’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $207.42, for a total transaction of $746,297.16. Following the completion of the sale, the senior vice president now directly owns 10,668 shares of the company’s stock, valued at $2,212,756.56. The disclosure for this sale can be found here. Insiders own 10.98% of the company’s stock.

Veeva Systems Price Performance

VEEV stock opened at $199.16 on Tuesday. Veeva Systems Inc. has a 1-year low of $160.21 and a 1-year high of $236.90. The firm has a fifty day moving average price of $220.78 and a two-hundred day moving average price of $202.82. The firm has a market cap of $32.13 billion, a price-to-earnings ratio of 61.85, a PEG ratio of 2.00 and a beta of 0.74.

Veeva Systems (NYSE:VEEV) last released its quarterly earnings results on Thursday, February 29th. The technology company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.81 by $0.11. The business had revenue of $630.62 million during the quarter, compared to analyst estimates of $620.75 million. Veeva Systems had a net margin of 22.24% and a return on equity of 11.26%. As a group, analysts expect that Veeva Systems Inc. will post 4.11 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Truist Financial boosted their target price on shares of Veeva Systems from $187.00 to $203.00 and gave the stock a “hold” rating in a research report on Friday, March 1st. Robert W. Baird boosted their target price on shares of Veeva Systems from $245.00 to $251.00 and gave the stock an “outperform” rating in a research report on Friday, March 1st. Stifel Nicolaus boosted their target price on shares of Veeva Systems from $205.00 to $250.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. UBS Group boosted their target price on shares of Veeva Systems from $185.00 to $235.00 and gave the stock a “neutral” rating in a research report on Monday, February 26th. Finally, Jefferies Financial Group lifted their price target on shares of Veeva Systems from $225.00 to $270.00 and gave the stock a “buy” rating in a research note on Monday, March 4th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $234.90.

Veeva Systems Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.